ENVB
Enveric Biosciences, Inc.
Price Chart
Latest Quote
$1.28
-0.02 (-1.54%)
Current Price
| Previous Close | $1.30 |
| Open | $1.31 |
| Day High | $1.33 |
| Day Low | $1.26 |
| Volume | 66,195 |
Stock Information
| Shares Outstanding | 4.03M |
| Cash Equivalents | $4.91M |
| Net Income | $-11.58M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.16M |
| EPS (TTM) | $-22.56 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-196K |
| Income | $-11.58M |
| Book/sh | $2.68 |
| Cash/sh | $1.22 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 10.66 |
| Current Ratio | 11.67 |
Returns & Margins
| ROA | -96.72% |
| ROE | -183.12% |
Ownership
| Insider Ownership | 10.81% |
| Institutional Ownership | 2.78% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.91 |
| P/B | 0.48 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.86 |
| SMA50 | $2.59 |
| SMA200 | $4.55 |
| RSI | 5.26 |
| ATR | 0.1734 |
| Shares Float | 3.54M |
| Short Float | 0.73% |
| Short Ratio | 0.06 |
| Volatility | 1.10 |
| Rel Volume | 0.32 |
Performance History
| Week | -22.89% |
| Month | -39.34% |
| Quarter | -34.69% |
| 6 Months | -75.57% |
| YTD | -65.12% |
| Year | -91.47% |
| 3 Years | -99.99% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.28 | 65,900 |
| 2026-06-17 | $1.30 | 96,200 |
| 2026-06-16 | $1.37 | 173,600 |
| 2026-06-15 | $1.48 | 346,300 |
| 2026-06-12 | $1.53 | 1,782,300 |
| 2026-06-11 | $1.66 | 112,200 |
| 2026-06-10 | $1.62 | 126,600 |
| 2026-06-09 | $1.60 | 158,600 |
| 2026-06-08 | $1.75 | 100,300 |
| 2026-06-05 | $1.80 | 181,700 |
| 2026-06-04 | $1.96 | 83,500 |
| 2026-06-03 | $1.98 | 120,900 |
| 2026-06-02 | $2.22 | 98,100 |
| 2026-06-01 | $2.26 | 62,900 |
| 2026-05-29 | $2.30 | 97,500 |
| 2026-05-28 | $2.32 | 131,100 |
| 2026-05-27 | $2.14 | 82,300 |
| 2026-05-26 | $2.23 | 103,100 |
| 2026-05-22 | $2.21 | 115,300 |
| 2026-05-21 | $2.22 | 118,400 |
| 2026-05-20 | $2.20 | 126,200 |
| 2026-05-19 | $2.11 | 917,000 |
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
đ° Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-02-23T00:43:00ZEnveric Biosciences reports EB-003 receptor engagement assay data
TipRanks âĸ 2026-02-20T13:09:22Z
Enveric Biosciences announces issuance of U.S. patent
TipRanks âĸ 2025-12-30T13:10:17Z
AbbVie's Bretisilocin Hit With Enveric IP Claim
GuruFocus.com âĸ 2025-10-15T18:48:06Z
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
Investing.com âĸ 2025-10-15T12:30:13ZPsychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
TipRanks âĸ 2025-06-27T15:50:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,774,448 | $9,632,266 | $18,296,675 | $19,961,444 |
| Other Income Expense | $2,567 | $65,990 | $1,030,148 | $9,300 |
| Other Non Operating Income Expenses | $2,567 | $65,990 | - | - |
| Net Non Operating Interest Income Expense | $-106 | $219 | $3,708 | $-5,249 |
| Total Other Finance Cost | $106 | $-219 | - | - |
| Operating Expense | $8,774,448 | $9,632,266 | $18,296,675 | $19,961,444 |
| General And Administrative Expense | $5,792,573 | $6,453,505 | $10,700,256 | $11,605,761 |
| Rent Expense Supplemental | - | $0 | $1,848,235 | $0 |
| Interest Expense | - | - | - | $5,249 |
| Interest Expense Non Operating | - | - | - | $5,249 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,771,987 | $-9,574,987 | $-17,310,773 | $-18,504,347 |
| Net Interest Income | $-106 | $219 | $3,708 | $-5,249 |
| Normalized Income | $-8,771,987 | $-9,574,987 | $-18,124,590 | $-18,512,955 |
| Net Income From Continuing And Discontinued Operation | $-8,771,987 | $-9,574,987 | $-17,310,773 | $-18,504,347 |
| Total Operating Income As Reported | $-8,774,448 | $-9,632,266 | $-16,448,440 | $-27,415,106 |
| Net Income Common Stockholders | $-12,131,472 | $-9,574,987 | $-17,458,761 | $-18,800,323 |
| Net Income | $-8,771,987 | $-9,574,987 | $-17,310,773 | $-18,504,347 |
| Net Income Including Noncontrolling Interests | $-8,771,987 | $-9,574,987 | $-17,291,732 | $-18,471,333 |
| Net Income Continuous Operations | $-8,771,987 | $-9,574,987 | $-17,291,732 | $-18,471,333 |
| Pretax Income | $-8,771,987 | $-9,566,057 | $-17,262,819 | $-19,957,393 |
| Operating Income | $-8,774,448 | $-9,632,266 | $-18,296,675 | $-19,961,444 |
| Depreciation Amortization Depletion Income Statement | $200,858 | $337,489 | $343,982 | $327,910 |
| Depreciation And Amortization In Income Statement | $200,858 | $337,489 | $343,982 | $327,910 |
| Interest Income | - | $219 | $3,708 | - |
| Interest Income Non Operating | - | $219 | $3,708 | - |
| Special Income Charges | - | - | $0 | $-7,453,662 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-36.24 | $-228.48 | $-1455.48 | $-195.00 |
| Basic EPS | $-36.24 | $-228.48 | $-1455.48 | $-195.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $216,331 | $692 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,573,590 | $-9,294,777 | $-18,918,793 | $-19,526,243 |
| Reconciled Depreciation | $200,858 | $337,489 | $408,030 | $435,201 |
| EBITDA (Bullshit earnings) | $-8,573,590 | $-9,294,777 | $-17,888,645 | $-19,516,943 |
| EBIT | $-8,774,448 | $-9,632,266 | $-18,296,675 | $-19,952,144 |
| Diluted Average Shares | $334,719 | $502,899 | $143,937 | $96,400 |
| Basic Average Shares | $334,719 | $502,899 | $143,937 | $96,400 |
| Diluted NI Availto Com Stockholders | $-12,131,472 | $-9,574,987 | $-17,458,761 | $-18,800,323 |
| Otherunder Preferred Stock Dividend | $3,359,485 | $0 | - | - |
| Tax Provision | $0 | $8,930 | $28,913 | $-1,486,060 |
| Research And Development | $2,781,017 | $2,841,272 | $7,252,437 | $8,027,773 |
| Selling General And Administration | $5,792,573 | $6,453,505 | $10,700,256 | $11,605,761 |
| Other Gand A | $5,792,573 | $6,453,505 | $8,852,021 | $11,605,761 |
| Total Unusual Items | - | $45,990 | $1,030,148 | $9,300 |
| Total Unusual Items Excluding Goodwill | - | $45,990 | $1,030,148 | $9,300 |
| Minority Interests | - | $0 | $-19,041 | $-33,014 |
| Gain On Sale Of Security | - | $45,990 | $1,030,148 | $7,462,962 |
| Rent And Landing Fees | - | $0 | $1,848,235 | $0 |
| Preferred Stock Dividends | - | - | $147,988 | $295,976 |
| Impairment Of Capital Assets | - | - | $0 | $7,453,662 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,177,541 | $1,550,625 | $1,745,404 | $14,292,238 |
| Total Assets | $5,095,941 | $3,082,543 | $4,299,840 | $19,552,925 |
| Total Non Current Assets | $159,234 | $347,959 | $718,309 | $1,120,988 |
| Goodwill And Other Intangible Assets | $0 | $42,182 | $210,932 | $379,686 |
| Current Assets | $4,936,707 | $2,734,584 | $3,581,531 | $18,431,937 |
| Current Deferred Assets | $43,247 | $0 | $567,603 | $0 |
| Prepaid Assets | $215,969 | $493,558 | $501,344 | $708,053 |
| Cash Cash Equivalents And Short Term Investments | $4,677,491 | $2,241,026 | $2,287,977 | $17,723,884 |
| Cash And Cash Equivalents | $4,677,491 | $2,241,026 | $2,287,977 | $17,723,884 |
| Cash Financial | $4,677,491 | $2,241,026 | $2,287,977 | $17,723,884 |
| Receivables | - | $0 | $224,607 | $0 |
| Taxes Receivable | - | $0 | $224,607 | $0 |
| Other Intangible Assets | - | - | - | $379,686 |
| Other Current Assets | - | - | - | $708,053 |
| Debt | ||||
| Total Debt | - | - | $0 | $63,820 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $0 |
| Current Debt And Capital Lease Obligation | - | - | - | $63,820 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $918,400 | $1,489,736 | $2,343,504 | $3,995,973 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $918,400 | $1,489,736 | $2,343,504 | $3,995,973 |
| Payables And Accrued Expenses | $918,400 | $1,489,736 | $2,294,426 | $2,168,930 |
| Payables | $766,768 | $1,015,738 | $1,241,101 | $463,275 |
| Total Tax Payable | $85,873 | $261,100 | $22,318 | $0 |
| Accounts Payable | $581,020 | $521,747 | $1,218,783 | $463,275 |
| Other Current Liabilities | - | $3,088 | $49,078 | $1,763,223 |
| Other Payable | - | $15,194 | - | - |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Taxes Liabilities | - | - | - | $0 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $4,177,541 | $1,592,807 | $1,956,336 | $14,671,924 |
| Total Equity Gross Minority Interest | $4,177,541 | $1,592,807 | $1,956,336 | $15,556,952 |
| Stockholders Equity | $4,177,541 | $1,592,807 | $1,956,336 | $14,671,924 |
| Gains Losses Not Affecting Retained Earnings | $-580,038 | $-594,517 | $-569,749 | $-536,734 |
| Other Equity Adjustments | $-580,038 | $-594,517 | $-569,749 | $-536,734 |
| Retained Earnings | $-114,846,492 | $-106,074,505 | $-96,499,518 | $-79,207,786 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $0 | $0 |
| Other Equity Interest | - | - | $-1,817,640 | - |
| Other | ||||
| Ordinary Shares Number | $1,061,533 | $678,002 | $182,621 | $138,551 |
| Share Issued | $1,061,533 | $678,002 | $182,621 | $138,551 |
| Tangible Book Value | $4,177,541 | $1,550,625 | $1,745,404 | $14,292,238 |
| Invested Capital | $4,177,541 | $1,592,807 | $1,956,336 | $14,671,924 |
| Working Capital | $4,018,307 | $1,244,848 | $1,238,027 | $14,435,964 |
| Total Capitalization | $4,177,541 | $1,592,807 | $1,956,336 | $14,671,924 |
| Additional Paid In Capital | $119,593,456 | $108,261,264 | $100,841,416 | $94,395,662 |
| Capital Stock | $10,615 | $565 | $1,827 | $20,782 |
| Common Stock | $10,615 | $565 | $1,827 | $20,782 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $151,632 | $473,998 | $1,053,325 | $1,705,655 |
| Dueto Related Parties Current | $99,875 | $232,891 | $0 | - |
| Net PPE | $159,234 | $305,777 | $507,377 | $741,302 |
| Accumulated Depreciation | $-675,552 | $-489,401 | $-357,711 | $-178,775 |
| Gross PPE | $834,786 | $795,178 | $865,088 | $920,077 |
| Other Properties | $807,402 | $769,105 | $836,709 | $894,940 |
| Machinery Furniture Equipment | $27,384 | $26,073 | $28,379 | $25,137 |
| Minority Interest | - | $0 | $0 | $885,028 |
| Capital Lease Obligations | - | - | $0 | $63,820 |
| Current Capital Lease Obligation | - | - | $0 | $63,820 |
| Long Term Capital Lease Obligation | - | - | - | $0 |
| Goodwill | - | - | - | $0 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,141,543 | $-7,726,139 | $-14,099,591 | $-17,730,888 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,141,543 | $-7,726,139 | $-14,094,411 | $-17,146,723 |
| Cash Flow From Continuing Operating Activities | $-8,141,543 | $-7,726,139 | $-14,094,411 | $-17,146,723 |
| Operating Gains Losses | $-2,565 | $-45,990 | $-1,034,354 | $-7,462,962 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $11,667 | $-584,165 |
| Cash Flow From Continuing Investing Activities | - | $0 | $11,667 | $-584,165 |
| Capital Expenditure | - | - | $-5,180 | $-584,165 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,881,266 | $3,373,892 | $0 | $17,222,099 |
| Financing Cash Flow | $10,579,507 | $7,673,834 | $-1,343,141 | $18,180,137 |
| Cash Flow From Continuing Financing Activities | $10,579,507 | $7,673,834 | $-1,343,141 | $18,180,137 |
| Net Common Stock Issuance | $5,881,266 | $3,373,892 | $0 | $17,222,099 |
| Common Stock Issuance | $5,881,266 | $3,373,892 | $0 | $17,222,099 |
| Repurchase Of Capital Stock | - | $0 | $-1,052,057 | $0 |
| Net Other Financing Charges | - | $-181,857 | $-291,084 | $958,038 |
| Net Preferred Stock Issuance | - | $0 | $-1,052,057 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $5,249 |
| Income Tax Paid Supplemental Data | $0 | $5,000 | $9,507 | $0 |
| End Cash Position | $4,677,491 | $2,241,026 | $2,287,977 | $17,723,884 |
| Beginning Cash Position | $2,241,026 | $2,287,977 | $17,723,884 | $17,355,999 |
| Effect Of Exchange Rate Changes | $-1,499 | $5,354 | $-10,022 | $-81,364 |
| Changes In Cash | $2,437,964 | $-52,305 | $-15,425,885 | $449,249 |
| Proceeds From Stock Option Exercised | $4,698,241 | $4,481,799 | $0 | $0 |
| Change In Working Capital | $-295,942 | $-423,243 | $-174,750 | $-217,660 |
| Change In Payables And Accrued Expense | $-546,880 | $-601,739 | $-103,848 | $263,686 |
| Change In Payable | $-546,880 | $-601,739 | $-103,848 | - |
| Change In Account Payable | $-413,864 | $-834,630 | $-103,848 | - |
| Change In Prepaid Assets | $250,938 | $178,496 | $-6,857 | $-374,058 |
| Other Non Cash Items | $-99,230 | $418,200 | $1,848,235 | - |
| Stock Based Compensation | $827,323 | $1,562,392 | $2,150,160 | $2,620,671 |
| Depreciation Amortization Depletion | $200,858 | $337,489 | $408,030 | $435,201 |
| Depreciation And Amortization | $200,858 | $337,489 | $408,030 | $435,201 |
| Amortization Cash Flow | $42,182 | $168,750 | $168,754 | $168,750 |
| Amortization Of Intangibles | $42,182 | $168,750 | $168,754 | $168,750 |
| Depreciation | $158,676 | $168,739 | $239,276 | $266,451 |
| Gain Loss On Investment Securities | $-2,565 | $-45,990 | $-1,030,148 | $-7,462,962 |
| Net Income From Continuing Operations | $-8,771,987 | $-9,574,987 | $-17,291,732 | $-18,471,333 |
| Preferred Stock Payments | - | $0 | $-1,052,057 | $0 |
| Net PPE Purchase And Sale | - | $0 | $11,667 | $-584,165 |
| Sale Of PPE | - | $0 | $16,847 | $0 |
| Purchase Of PPE | - | $0 | $-5,180 | $-584,165 |
| Gain Loss On Sale Of PPE | - | $0 | $-4,206 | $0 |
| Change In Other Working Capital | - | - | $-64,045 | $-107,288 |
| Asset Impairment Charge | - | - | $0 | $7,453,662 |
| Deferred Tax | - | - | $0 | $-1,504,302 |
| Deferred Income Tax | - | - | $0 | $-1,504,302 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | $-107,288 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-14